Case | Survey | Countries, % GPs starting treatment | P-valuea | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Age | Vitality status | TSH, mU/L | Total (n = 526) | Netherlands n = 129 | Germany n = 61 | England n = 22 | Ireland n = 21 | Switzerland n = 262 | New Zealand n = 31 | ||
1 | 70 | Vital | 6 | 32 | 16 | 75 | 0 | 43 | 34 | 7 | <0.01 |
2 | 70 | Vulnerable | 6 | 26 | 13 | 60 | 5 | 33 | 28 | 8 | <0.01 |
3 | 70 | Vital | 15 | 77 | 59 | 92 | 77 | 89 | 81 | 84 | <0.01 |
4 | 70 | Vulnerable | 15 | 74 | 60 | 88 | 77 | 94 | 77 | 65 | <0.01 |
5 | 85 | Vital | 6 | 23 | 13 | 52 | 5 | 31 | 23 | 10 | <0.01 |
6 | 85 | Vulnerable | 6 | 26 | 8 | 57 | 5 | 53 | 27 | 19 | <0.01 |
7 | 85 | Vital | 15 | 70 | 53 | 84 | 77 | 81 | 75 | 68 | <0.01 |
8 | 85 | Vulnerable | 15 | 68 | 53 | 75 | 73 | 75 | 74 | 52 | <0.01 |
Overallb | 50 | 34 | 73 | 40 | 62 | 52 | 39 | 0.05c |